CANF
Time to buy CANF?$3.36
+$0.05 (1.49%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
CANF ran from $2.83 in late April to $4.08 on April 30, 2026 off micro-cap momentum and fresh biotech updates, then settled back near $3.41 as the spike cooled.
The stock has the potential to go down if it loses $3.00, and that could open a fade toward $2.83 or lower. Any fresh dilution, warrant-related selling, or another financing headline would likely speed up that move.
If CANF holds the $3.00 to $3.20 zone and buyers keep respecting that post-spike base, a push back toward $4.00 to $4.50 is on the table. Resistance at $3.90 to $4.08 is the first hurdle, especially with the company now advancing Namodenoson into a planned Phase 2b pancreatic cancer study.
Analyst Ratings
Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Earnings
We don't currently have information about Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)'s earnings.